Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'Herceptin' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 69 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Eccles, SA
      Monoclonal antibodies targeting cancer: 'magic bullets' or just the trigger?

      BREAST CANCER RESEARCH
    2. Buchler, P; Reber, HA; Buchler, MC; Roth, MA; Buchler, MW; Friess, H; Isacoff, WH; Hines, OJ
      Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin)

      JOURNAL OF GASTROINTESTINAL SURGERY
    3. Singletary, SE
      Systemic treatment after sentinel lymph node biopsy in breast cancer: Who,what, and why?

      JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
    4. Kaptain, S; Tan, LK; Chen, BY
      Her-2/neu and breast cancer

      DIAGNOSTIC MOLECULAR PATHOLOGY
    5. Prange, W; Schirmacher, P
      Absence of therapeutically relevant c-erbB-2 expression in human hepatocellular carcinomas

      ONCOLOGY REPORTS
    6. Baselga, J
      Clinical trials of Herceptin (R) (trastuzumab)

      EUROPEAN JOURNAL OF CANCER
    7. Vogel, C; Cobleigh, MA; Tripathy, D; Gutheil, JC; Harris, LN; Fehrenbacher, L; Slamon, DJ; Murphy, M; Novotny, WF; Burchmore, M; Shak, S; Stewart, SJ
      First-line, single-agent Herceptin (R) (trastuzumab) in metastatic breast cancer: a preliminary report

      EUROPEAN JOURNAL OF CANCER
    8. Bell, R
      Duration of therapy in metastatic breast cancer: management using Herceptin (R)

      ANTI-CANCER DRUGS
    9. Merimsky, O; Staroselsky, A; Inbar, M; Schwartz, Y; Wigler, N; Mann, A; Marmor, S; Greif, J
      Correlation between c-erbB-4 receptor expression and response to gemcitabine-cisplatin chemotherapy in non-small-cell lung cancer

      ANNALS OF ONCOLOGY
    10. Menard, S; Casalini, P; Campiglio, M; Pupa, S; Agresti, R; Tagliabue, E
      HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer

      ANNALS OF ONCOLOGY
    11. Lane, HA; Motoyama, AB; Beuvink, I; Hynes, NE
      Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling

      ANNALS OF ONCOLOGY
    12. Baselga, J; Albanell, J
      Mechanism of action of anti-HER2 monoclonal antibodies

      ANNALS OF ONCOLOGY
    13. Leyland-Jones, B; Arnold, A; Gelmon, K; Verma, S; Ayoub, JP; Seidman, A; Dias, R; Howell, J; Rakhit, A
      Pharmacologic insights into the future of trastuzumab

      ANNALS OF ONCOLOGY
    14. Baselga, J
      Phase I and II clinical trials of trastuzumab

      ANNALS OF ONCOLOGY
    15. Eiermann, W
      Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data

      ANNALS OF ONCOLOGY
    16. Gianni, L
      Tolerability in patients receiving trastuzumab with or without chemotherapy

      ANNALS OF ONCOLOGY
    17. Bell, R
      Ongoing trials with trastuzumab in metastatic breast cancer

      ANNALS OF ONCOLOGY
    18. Smith, I
      Future directions in the adjuvant treatment of breast cancer: The role of trastuzumab

      ANNALS OF ONCOLOGY
    19. Piccart, MJ
      Proposed treatment guidelines for HER2-positive metastatic breast cancer in Europe

      ANNALS OF ONCOLOGY
    20. Schaller, G; Evers, K; Papadopoulos, S; Ebert, A; Buhler, H
      Current use of HER2 tests

      ANNALS OF ONCOLOGY
    21. Thor, A
      HER2 - a discussion of testing approaches in the USA

      ANNALS OF ONCOLOGY
    22. Schnitt, SJ
      Breast cancer in the 21st century: Neu opportunities and neu challenges

      MODERN PATHOLOGY
    23. Saijo, N; Tamura, T; Yamamoto, N; Nishio, K
      New strategies for cancer therapy in the 21st century

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    24. Skalova, A; Starek, I; Kucerova, V; Szepe, P; Plank, L
      Salivary duct carcinoma - A highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression

      PATHOLOGY RESEARCH AND PRACTICE
    25. Turatti, F; Mezzanzanica, D; Nardini, E; Luison, E; Maffioli, L; Bombardieri, E; de Lalla, C; Canevari, S; Figini, M
      Production and validation of the pharmacokinetics of a single-chain Fv fragment of the MGR6 antibody for targeting of tumors expressing HER-2

      CANCER IMMUNOLOGY IMMUNOTHERAPY
    26. Mokbel, K; Hassanally, D
      From HER2 to herceptin

      CURRENT MEDICAL RESEARCH AND OPINION
    27. Meden, H; Beneke, A; Hesse, T; Novophashenny, I; Wischnewsky, M
      Weekly intravenous recombinant humanized anti-P185(HER2) monoclonal antibody (herceptin) plus docetaxel in patients with metastatic breast cancer: A pilot study

      ANTICANCER RESEARCH
    28. Brockhoff, G; Heiss, P; Schlegel, J; Hofstaedter, F; Knuechel, R
      Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells

      CYTOMETRY
    29. Mayfield, S; Vaughn, JP; Kute, TE
      DNA strand breaks and cell cycle perturbation in Herceptin treated breast cancer cell lines

      BREAST CANCER RESEARCH AND TREATMENT
    30. Schneider, JW; Chang, AY; Rocco, TP
      Cardiotoxicity in signal transduction therapeutics: ErbB2 antibodies and the heart

      SEMINARS IN ONCOLOGY
    31. Hortobagyi, GN; Perez, EA
      Integration of trastuzumab into adjuvant systemic therapy of breast cancer: Ongoing and planned clinical trials

      SEMINARS IN ONCOLOGY
    32. Slichenmyer, WJ; Fry, DW
      Anticancer therapy targeting the ErbB family of receptor tyrosine kinases

      SEMINARS IN ONCOLOGY
    33. Gerber, B; Krause, A; Markmann, S; Reimer, T; Fietkau, R; Muller, H
      Effectiveness of trastuzumab (Herceptin (TM)) in a patient with locally recurrent breast cancer after cardiac failure caused by severe cytotoxic pretreatment

      ONCOLOGY
    34. Yarden, Y
      Biology of HER2 and its importance in breast cancer

      ONCOLOGY
    35. Baselga, J
      Herceptin((R)) alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: Pivotal trials

      ONCOLOGY
    36. Leyland-Jones, B
      Dose scheduling - Herceptin (R)

      ONCOLOGY
    37. Vogel, CL; Cobleigh, MA; Tripathy, D; Gutheil, JC; Harris, LN; Fehrenbacher, L; Slamon, DJ; Murphy, M; Novotny, WF; Burchmore, M; Shak, S; Stewart, SJ
      First-line Herceptin (R) monotherapy in metastatic breast cancer

      ONCOLOGY
    38. Dieras, V; Beuzeboc, P; Laurence, V; Pierga, JY; Pouillart, P
      Interaction between Herceptin((R)) and taxanes

      ONCOLOGY
    39. Winer, EP; Burstein, HJ
      New combinations with Herceptin((R)) in metastatic breast cancer

      ONCOLOGY
    40. Cook-Bruns, N
      Retrospective analysis of the safety of Herceptin((R)) immunotherapy in metastatic breast cancer

      ONCOLOGY
    41. Piccart, M; Lohrisch, C; Di Leo, A; Larsimont, D
      The predictive value of HER2 in breast cancer

      ONCOLOGY
    42. Leyland-Jones, B; Smith, I
      Role of Herceptin (R) in primary breast cancer: Views from North America and Europe

      ONCOLOGY
    43. Rusnak, JM; Kisabeth, RM; Herbert, DP; McNeil, DM
      Pharmacogenomics: Aa clinician's primer on emerging technologies for improved patient care

      MAYO CLINIC PROCEEDINGS
    44. Bartlett, JMS; Going, JJ; Mallon, EA; Watters, AD; Reeves, JR; Stanton, P; Richmond, J; Donald, B; Ferrier, R; Cooke, TG
      Evaluating HER2 amplification and overexpression in breast cancer

      JOURNAL OF PATHOLOGY
    45. Pilon, SA; Piechocki, MP; Wei, WZ
      Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody

      JOURNAL OF IMMUNOLOGY
    46. Bougeret, C; Jiang, SX; Keydar, I; Avraham, H
      Functional analysis of Csk and CHK kinases in breast cancer cells

      JOURNAL OF BIOLOGICAL CHEMISTRY
    47. Uno, M; Otsuki, T; Kurebayashi, J; Sakaguchi, H; Isozaki, Y; Ueki, A; Yata, K; Fujii, T; Hiratsuka, J; Akisada, T; Harada, T; Imajo, Y
      Anti-HER2-antibody enhances irradiation-induced growth inhibition in head and neck carcinoma

      INTERNATIONAL JOURNAL OF CANCER
    48. Carson, WE; Parihar, R; Lindemann, MJ; Personeni, N; Dierksheide, J; Meropol, NJ; Baselga, J; Caligiuri, MA
      Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells

      EUROPEAN JOURNAL OF IMMUNOLOGY
    49. Lyon, E; Millson, A; Lowery, MC; Woods, R; Wittwer, CT
      Quantification of HER2/neu gene amplification by competitive PCR using fluorescent melting curve analysis

      CLINICAL CHEMISTRY
    50. Duffy, MJ
      Biochemical markers in breast cancer: which ones are clinically useful?

      CLINICAL BIOCHEMISTRY
    51. Reilly, RT; Machiels, JPH; Emens, LA; Ercolini, AM; Okoye, FI; Lei, RY; Weintraub, D; Jaffee, EM
      The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors

      CANCER RESEARCH
    52. Murillo, H; Schmidt, LJ; Tindall, DJ
      Tyrphostin AGS25 triggers p38 mitogen-activated protein kinase-dependent apoptosis in androgen-independent prostate cancer cells C4 and C4-2

      CANCER RESEARCH
    53. Park, BW; Zhang, HT; Wu, CJ; Berezov, A; Zhang, X; Dua, R; Wang, Q; Kao, G; O'Rourke, DM; Greene, MI; Murali, R
      Rationally designed anti-HER2/neu peptide mimetic disables p185(HER2/neu) tyrosine kinases in vitro and in vivo

      NATURE BIOTECHNOLOGY
    54. Kakar, S; Puangsuvan, N; Stevens, JM; Serenas, R; Mangan, G; Sahai, S; Mihalov, ML
      HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: Comparison of results and correlation with survival

      MOLECULAR DIAGNOSIS
    55. Barcus, ME; Powers, CN
      Evaluation of endocrine neoplasms using fine needle aspiration biopsy

      ENDOCRINE PATHOLOGY
    56. Schwartz, MK; Smith, C; Schwartz, DC; Dnistrian, A; Neiman, I
      Monitoring therapy by serum HER-2/neu

      INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS
    57. Untch, M; Crohns, C; Kahlert, S; Hepp, H
      Anthracyclines and herceptin (R): New treatment option for patients with metastatic breast cancer

      ONKOLOGIE
    58. Scheurle, D; Jahanzeb, M; Aronsohn, RS; Watzek, L; Narayanan, R
      HER-2/neu expression in archival non-small cell lung carcinomas using FDA-approved Hercep Test

      ANTICANCER RESEARCH
    59. Brown, RE; Bernath, AM; Levis, GO
      HER-2/neu protein-receptor-positive breast carcinoma: An immunologic perspective

      ANNALS OF CLINICAL AND LABORATORY SCIENCE
    60. Wu, JT; Zhang, P; Bentz, JS
      Quantification of HER2 oncoprotein in fine-needle aspirates of the breast

      ANNALS OF CLINICAL AND LABORATORY SCIENCE
    61. Ellis, IO; Dowsett, M; Bartlett, J; Walker, R; Cooke, T; Gullick, W; Gusterson, B; Mallon, E; Lee, PB
      Recommendations for HER2 testing in the UK

      JOURNAL OF CLINICAL PATHOLOGY
    62. Konecny, G; Pegram, M; Untch, M; Thomssen, C; Janicke, F; Hepp, H; Slamon, DJ
      HER-2/neu as a predictive marker in breast cancer

      GEBURTSHILFE UND FRAUENHEILKUNDE
    63. Carr, JA; Havstad, S; Zarbo, RJ; Divine, G; Mackowiak, P; Velanovich, V
      The association of HER-2/neu amplification with breast cancer recurrence

      ARCHIVES OF SURGERY
    64. Hoang, MP; Sahin, AA; Ordonez, NG; Sneige, N
      HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma

      AJCP. American journal of clinical pathology
    65. Penault-Llorca, F; Jacquemier, J; Le Doussal, V; Voigt, JJ
      Qualify challenge for immunohistochemistry: example of the ERBB-2 status in breast cancer

      ANNALES DE PATHOLOGIE
    66. Colbern, GT; Hiller, AJ; Musterer, RS; Working, PK; Henderson, IC
      Antitumor activity of Herceptin (R) in combination with STEALTH (R) liposomal cisplatin or nonliposomal cisplatin in a HER2 positive human breast cancer model

      JOURNAL OF INORGANIC BIOCHEMISTRY
    67. Konecny, G; Untch, M; Pegram, M
      Herceptin in the treatment of metastatic breast cancer

      GYNAKOLOGE
    68. Beuzeboc, P; Scholl, S; Garau, XS; Vincent-Salomon, A; de Cremoux, P; Couturier, J; Palangie, T; Pouillard, P
      Herceptin, a monoclonal humanized antibody anti-HER2: a major therapeutic progress in breast cancers overexpressing this oncogene

      BULLETIN DU CANCER
    69. GOLDHIRSCH A; COATES AS; CASTIGLIONEGERTSCH M; GELBER RD
      NEW TREATMENTS FOR BREAST-CANCER - BREAKTHROUGHS FOR PATIENT-CARE OR JUST STEPS IN THE RIGHT DIRECTION

      Annals of oncology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/10/20 alle ore 12:19:48